Palbociclib (Ibrance®)

Assessment Status Assessment process complete
Drug Palbociclib
Brand Ibrance®
Indication For the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.
Assessment Process
Rapid review commissioned 20/09/2016
Rapid review completed 28/09/2016
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 10/10/2016
Pre-submission consultation with Applicant 11/11/2016
Full submission received from Applicant 20/12/2016
Preliminary review sent to Applicant 24/05/2017
NCPE assessment re-commenced 30/05/2017
Follow-up to preliminary review sent to Applicant 13/06/2017
NCPE assessment re-commenced 15/06/2017
Additional follow-up to Preliminary Review sent to Applicant 16/06/2017
NCPE assessment re-commenced 21/06/2017
Factual accuracy sent to Applicant 04/07/2017
NCPE assessment completed 28/07/2017
NCPE assessment outcome Reimbursement not recommended.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations; June 2018.